证券代码：600257 证券简称：大湖股份 公告编号：2023-062 大湖水殖股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性 承担个别及连带责任。 重要内容提示： ●根据《上海证券交易所上市公司自律监管指南第 1 号——公 告格式（2023 年 4 月修订）》的规定，大湖水殖股份有限公司（以 下简称"公司"）对 2023 年年度预计担保额度范围内的担保进展情 况按月度进行汇总披露。 ●本月新增实际提供担保金额共计为人民币 6,000 万元。 ●截止本公告披露日，公司在 2023 年年度预计担保额度范围内 为下属子公司已实际提供的担保余额为 20,120 万元（含本月新增担 保），占公司最近一期经审计的净资产的比例为 22.87%。 ●在本次披露的 2023 年年度预计担保额度范围内的担保进展中， 新签担保协议不涉及反担保。 ●截止本公告披露日，公司无对外担保逾期情况。 一、年度担保预计情况概述 公司于 2023 年 1 月 19 日召开的第八届董事会第二十六次会议 和 2023 年 2 月 6 ...

关于控股子公司东方华康医疗管理有限公司 2023 年 1 月至 9 月主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 一、控股子公司 2023 年 1 月至 9 月的主要经营数据 2023 年 1 月至 9 月，经公司财务部初步测算，大湖水殖股份有 限公司（以下简称"公司"）控股子公司东方华康医疗管理有限公司 （以下简称"东方华康"）预计实现营业收入约 2 亿元，较去年同期 增长约 23%；预计实现净利润约 5,000 万，较去年同期增长约 130%。 其中无锡国济康复医院与无锡国济护理院预计实现营业收入约 6,200 万元，较去年同期增长约 45%；预计实现净利润约 1,400 万元，去年 同期为亏损 534 万元。 东方华康 2023 年 1-9 月预计业绩增长，主要是由于 2023 年全国 经济逐渐恢复，市场有所回暖，业务拓展渠道放开所致，发展态势较 好。 证券代码：600257 证券简称：大湖股份 公告编号：2023-061 大湖水殖股份有限公司 本次公司控股子公司主要经营数据预计系公司财务 ...

证券代码：600257 证券简称：大湖股份 公告编号：2023-060 大湖水殖股份有限公司 ●投资者可于 2023 年 09 月 12 日(星期二)至 09 月 18 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 925286482@qq.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 大湖水殖股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地 了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 09 月 19 日下午 15:00-16:30 举行 2023 年半年度业绩说明会，就投 资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年半年度经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导 ...

公司于 2023 年 8 月 31 日收到西藏泓杉通知，西藏泓杉将其持有 本公司的部分股票解除质押，具体情况如下： 证券代码：600257 证券简称：大湖股份 公告编号：2023-059 大湖水殖股份有限公司 关于控股股东部分股票解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： ●西藏泓杉科技发展有限公司（以下简称"西藏泓杉"）持有大 湖水殖股份有限公司（以下简称"公司"或"本公司"）104,631,211 股股票，占本公司总股本的比例为 21.74%，是公司的控股股东。本 次部分股票解除质押后，西藏泓杉累计质押股票 28,840,000 股，占 其所持有本公司股数的比例为 27.56%,占本公司总股本的比例为 5.99%。 一、上市公司部分股份解除质押 2023 年 9 月 1 日 | 股东名称 | 西藏泓杉 | | --- | --- | | 本次解除质押股份 | 22,500,000 股 | | 占其所持股份比例 | 21.50% | | 占公司总股本比例 | 4.68% | | 解 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately RMB 590.1 million, representing a 9.35% increase compared to RMB 539.6 million in the same period last year[20]. - The net profit attributable to shareholders of the listed company was a loss of approximately RMB 11.2 million, an improvement of 21.63% from a loss of RMB 14.2 million in the previous year[20]. - The basic earnings per share for the first half of 2023 was a loss of RMB 0.0232, an improvement of 22.99% from a loss of RMB 0.0301 in the same period last year[22]. - The company reported a total non-operating loss of 5,791,143.24, with significant impacts from minority interests and income tax adjustments[25]. - The company’s total revenue for the first half of 2023 was approximately CNY 590.1 million, representing a 9.35% increase compared to CNY 539.6 million in the same period last year[56]. - The company’s total comprehensive income for the first half of 2023 was -¥3,954,115.16, compared to -¥12,408,701.60 in the same period of 2022, indicating a significant reduction in comprehensive losses[127]. - The company reported a net asset value of 29.8032 million RMB for Dehai Medical Trade as of May 31, 2023[68]. - The company reported a total comprehensive income loss of 13,153,407.74 RMB for the first half of 2023[146]. Cash Flow and Assets - The net cash flow from operating activities was a negative RMB 69.3 million, which is a 33.32% improvement compared to a negative RMB 104.0 million in the same period last year[21]. - The total assets at the end of the reporting period were approximately RMB 2.11 billion, down 2.37% from RMB 2.16 billion at the end of the previous year[21]. - The total current assets as of June 30, 2023, amounted to ¥931,588,701.29, a decrease from ¥953,359,108.68 as of December 31, 2022, reflecting a decline of approximately 2.5%[116]. - Cash and cash equivalents decreased to ¥164,576,512.30 from ¥231,449,101.93, representing a decline of about 29%[116]. - The company’s total liabilities for Hangzhou Jincheng were reported at 167.55 million RMB[69]. - The total liabilities decreased from ¥1,160,504,202.31 to ¥1,113,743,822.07, a decline of about 4.03%[118]. - The total fair value of financial assets at the end of the period was 157,214,052.3 RMB, with a decrease of 668,359.74 RMB during the period[65]. Operational Segments and Strategies - The company operates in two main segments: health product production and sales, and health medical services, focusing on the synergy between these two areas[26]. - The aquaculture segment emphasizes a full industry chain model, including seed breeding, ecological farming, professional fishing, deep processing, and sales, supported by a flexible logistics supply chain[27]. - The company aims to expand its rehabilitation and nursing services across the Yangtze River Delta, targeting various demographics including the elderly and patients[28]. - The company is positioned to benefit from government initiatives supporting the development of modern facilities in aquaculture and cold chain logistics[32]. - The company’s strategy includes leveraging modern technology to enhance aquaculture efficiency and expand production capacity[31]. - The company aims to transform into a comprehensive health industry by integrating health products and services, optimizing its processing chain, and expanding sales channels[46]. Market Trends and Growth Potential - The pre-prepared dishes market in China is expected to exceed 800 billion yuan by 2025, with the market for sauerkraut fish pre-prepared dishes projected to reach 1.69 billion yuan, indicating significant growth potential in the sector[37]. - The rehabilitation medical market in China is projected to exceed 220 billion yuan by 2025, driven by an aging population and increasing rehabilitation needs[41]. - The aquatic product processing industry is characterized by low concentration, with only 31.28% of total aquatic product output being processed, suggesting a broad future development potential[36]. - The demand for pre-prepared aquatic dishes is becoming a new growth point in the aquatic product industry, driven by changing consumer habits and the rise of the "stay-at-home" economy[37]. - The white liquor industry is experiencing a structural adjustment with a shift towards high-quality development, supported by multiple industry policies aimed at standardization and quality improvement[39]. Research and Development - Research and development expenses surged by 105.27%, reaching CNY 402,439.14 compared to CNY 196,052.02 in the previous year[56]. - The company has made substantial progress in research and development, achieving breakthroughs in fish breeding and processing technologies, which will support future production capabilities[45]. - The company has received significant awards for its technological innovations in aquaculture, including first-class awards for key technology research in freshwater fish processing[45]. Corporate Governance and Structure - The company appointed several new executives, including a new chairman and multiple vice presidents, during the recent board restructuring[75]. - The company has not disclosed any employee stock ownership plans or other incentive measures during the reporting period[78]. - The company has not reported any changes in its controlling shareholder or actual controller during the reporting period[112]. - The total number of ordinary shareholders as of the end of the reporting period is 53,393[106]. Sustainability and Social Responsibility - The company is committed to sustainable practices in aquaculture, aligning with national environmental protection initiatives to ensure ecological balance[47]. - Total donations for rural revitalization and poverty alleviation projects amounted to CNY 121,800, with CNY 100,000 donated to Yanglouping Village and CNY 21,800 for organic fertilizer[81]. - The company adopts an ecological breeding model for fish farming, which aligns with national green development initiatives[80].

证券代码：600257 证券简称：大湖股份 公告编号：2023-050 大湖水殖股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： ●大湖水殖股份有限公司（以下简称"公司"）股票于 2023 年 8 月 24 日、25 日、28 日连续 3 个交易日内收盘价涨幅偏离值累计超过 20%，根据《上海证券交易所股票上市规则》的有关规定，属于股票 交易异常波动情形。 ●经公司自查，并书面征询公司控股股东、实际控制人，截止本 公告披露日，除了已经披露的事项，不存在应披露而未披露的重大事 项。 ●公司 2023 年 8 月 24 日、25 日、28 日的换手率分别是 22.82%、 3.19%、16.79%，8 月 24 日、28 日的公司交易换手率明显高于前期水 平，二级市场交易和估值受多方面因素影响，股票涨跌的波动风险较 大，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 公司股票于 2023 年 8 月 24 日、25 日、28 ...

证券代码：600257 证券简称：大湖股份 编号：2023-049 经自查，公司目前生产经营活动一切正常，外部环境未发生重大 变化。公司计划于 2023 年 8 月 31 日披露《2023 年半年度报告》，公 司 2023 年上半年的具体生产经营情况，届时请关注上海证券交易所 网站（www.sse.com.cn）上披露的内容。 （二）重大事项情况 大湖水殖股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 一、股票交易异常波动的具体情况 大湖水殖股份有限公司（以下简称"公司"）股票于 2023 年 8 月 23 日、24 日连续 2 个交易日内收盘价涨幅偏离值累计超过 20%，属 于股票交易异常波动情形，公司于 2023 年 8 月 24 日发布了《大湖水 殖股份有限公司关于股票交易异常波动的公告》，具体内容详见上海 证券交易所网站（http：//www.sse.com.cn）披露的公告（公告编号： 2023-048）。 2023 年 8 月 25 日，公司股票继续涨停。自 2023 年 ...

●大湖水殖股份有限公司（以下简称"公司"）股票于 2023 年 8 月 23 日、24 日连续 2 个交易日内收盘价涨幅偏离值累计超过 20%， 根据《上海证券交易所股票上市规则》的有关规定，属于股票交易异 常波动情形。 ●经公司自查，并书面征询公司控股股东、实际控制人，截止本 公告披露日，除了已经披露的事项，不存在应披露而未披露的重大事 项。 证券代码：600257 证券简称：大湖股份 公告编号：2023-048 大湖水殖股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： 一、股票交易异常波动的具体情况 经公司自查并向公司控股股东及实际控制人书面征询，核实公司 控股股东、实际控制人不存在应披露而未披露的引起股票交易异常波 公司股票于 2023 年 8 月 23 日、24 日连续 2 个交易日内收盘价 涨幅偏离值累计超过 20%，根据《上海证券交易所股票上市规则》的 有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 动的重大事项 ...

湖南启元律师事务所 关于大湖水殖股份有限公司 2023年第三次临时股东大会的 法律意见书 二零二三年八月七日 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 等法律、法规和规范性文件以及《大湖水殖股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，我们依法审核了公司提供的下列资料： 1、刊登在 2023 年 7 月 22 日上海证券交易所网站（http://www.sse.com.cn/） 上的公司第九届董事会第二次会议决议公告（以下简称"《董事会决议》"）及刊 登在 2023 年 7 月 22 日上海证券交易所网站（http://www.sse.com.cn/）上的关于 召开公司 2023 年第三次临时股东大会的通知（以下简称"《股东大会通知》"）； 为出具法律意见书，本律师特作声明如下： 2、出席会议股东或其代理人的资格、身份证明文件等； 3、公司本次股东大会股权登记日的股东名册、出席现场会议的股东的到会 登记记录及凭证资料； 4、公司本次股东大会会议文件。 湖南 ...

Financial Performance - The company's operating revenue for 2021 was approximately CNY 1.29 billion, representing a 37.99% increase compared to CNY 936.52 million in 2020[21]. - The net profit attributable to shareholders for 2021 was a loss of approximately CNY 180.12 million, a decrease of 4,417.79% compared to a profit of CNY 4.17 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately CNY 96.42 million, a significant increase of 387.10% compared to a negative cash flow of CNY 33.58 million in 2020[22]. - Total assets at the end of 2021 were approximately CNY 2.34 billion, an increase of 18.89% from CNY 1.97 billion at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 18.4% to approximately CNY 949.43 million at the end of 2021, down from CNY 1.16 billion at the end of 2020[22]. - The basic and diluted earnings per share for 2021 were both -0.37 RMB, a decrease of 4,352.87 percentage points compared to the previous year[23]. - The weighted average return on equity was -17.20%, down 17.56 percentage points from the previous year[23]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥96,420,908.67, compared to a negative cash flow of ¥33,584,944.13 in the previous year, marking a 387.10% improvement[55]. - The company reported a net loss of CNY 147,629,932.28 in retained earnings, compared to a profit of CNY 42,924,427.31 in the previous year[174]. - The total comprehensive loss for 2021 was approximately -¥197.95 million, compared to a comprehensive income of ¥21.27 million in 2020[180]. Business Segments and Operations - The company operates two main business segments: health product production and sales, and health medical service management, focusing on synergistic development[45]. - The aquaculture division emphasized high-quality breeding and the development of organic fresh food products[33]. - The revenue from the aquaculture segment accounted for 58.65% of total revenue, representing a year-on-year growth of 24.36%, with frozen aquatic products sales increasing by 280.16%[35]. - The health liquor segment's revenue share was 10.86%, showing a significant year-on-year increase of 49.95%[36]. - The health medical services segment's revenue share reached 16.74%, with a remarkable year-on-year growth of 530.07%[38]. - The company is focusing on the development of a "medical, nursing, and rehabilitation" integrated model in its health medical services[38]. - The company has established partnerships with well-known medical institutions to enhance its brand influence and service quality[38]. - The company is actively pursuing a strategic transformation towards the health industry, integrating health products and services[38]. - The company has established a comprehensive freshwater fish industry chain, emphasizing quality management and obtaining multiple certifications, including ISO9001 and organic product certification[46]. Market and Competitive Landscape - The company faces various operational risks, including market competition and food safety risks, as detailed in the management discussion section[9]. - The company faces competition risks in the market for its natural fish products, which have lower yields compared to pond-raised fish[78]. - The company faces risks in the white liquor industry due to intense competition and the potential market squeeze from national brands, as its products are categorized as regional brands[79]. - The demand for high-end liquor products is increasing, with a significant shift towards premium brands due to rising consumer health awareness and disposable income[44]. - The rehabilitation medical industry in China is projected to grow rapidly, with an expected market size exceeding 220 billion yuan by 2025, reflecting a compound annual growth rate of 20.60% from 2016 to 2025[44]. Governance and Management - The company held one annual general meeting and two extraordinary general meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[83]. - The board of directors consists of five members, including two independent directors, and has established four specialized committees to enhance governance and oversight[84]. - The total remuneration for the board members and senior management during the reporting period amounted to 4.5176 million yuan[89]. - The company has maintained a stable management team with no changes in shareholding among directors and supervisors[89]. - The company has a diverse management background with members having experience in various sectors including finance and project management[90]. - The company has established specialized committees within the board, including an audit committee and a strategic committee[103]. Financial Position and Assets - The company's total assets amounted to RMB 1,671,235,752.66 in 2021, compared to RMB 1,632,143,258.27 in 2020, reflecting a growth of 2.4%[177]. - Total liabilities reached CNY 1,265,140,435.82, compared to CNY 669,327,720.34 in 2020, reflecting a substantial increase of around 89%[174]. - The company's total equity decreased to RMB 1,017,750,548.45 in 2021 from RMB 1,151,086,977.23 in 2020, a decline of 11.6%[177]. - The company has pledged 368,078,828.90 RMB of subsidiary net assets to secure a bank loan for acquiring 60% of Dongfang Huakang Medical Management Co., Ltd.[71]. - The company has engaged in cash asset management, with a total of ¥20,000,000 in bank fixed-term wealth management and ¥30,000,000 in structured deposits[153]. Strategic Initiatives and Future Outlook - The company plans to enhance brand marketing and product innovation to strengthen its market position in the health food sector[33]. - The company is implementing a dual-channel marketing strategy, combining online and offline sales, and targeting both B2B and B2C markets[35]. - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[196]. - The company expects net profits for 2022, 2023, 2024, and 2025 to be CNY 45 million, CNY 60 million, CNY 80 million, and CNY 80 million respectively, totaling CNY 245 million over five years[128]. Social Responsibility and Environmental Impact - The company has donated a total of 268,200 CNY to support rural revitalization projects, with specific contributions of 150,000 CNY to the Yanglouping Village project and 100,000 CNY to the Dongliuxi Village project[122]. - The company emphasizes environmental protection by adopting an ecological breeding model that reduces carbon emissions and promotes sustainable development[117]. - The company has released over 100 million high-quality fish fry to protect the aquatic ecological environment over the past decade[120].